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Abstract______________________________________________________________________ 
 The L2 minor capsid protein of human papillomavirus is one of two structural proteins 
that comprise the icosahedral shell.  The icosahedron contains 72 pentameric capsomeres, each 
of which is stabilized by the formation of hydrophobic, intermolecular bonds between the n- and 
c-terminal domains of the L2 minor capsid protein and the L1 major capsid proteins.  In addition 
to its structural role, L2 has also been implicated in the cellular entry of the virion and the 
nuclear localization of the viral genome.  During the late phase of viral infection, the L1 and L2 
proteins are synthesized in the cytoplasm of the differentiated epithelial cells.  From the 
cytoplasm, the structural proteins are then transported through the nuclear pore complex into the 
cell nucleus where they encapsulate the replicated viral DNA in order to form new virions.  
Previous experiments conducted in the Moroianu lab by Shahan Mamoor suggest that high risk 
HPV16 L2 minor capsid protein may also undergo nuclear export.  Two potential, leucine-rich 
nuclear export signals (NESs) have been identified in the HPV16 L2 sequence, one in the n-
terminus (51MGVFFGGLGI60) and one in the c-terminus (462LPYFFDSVSL471).  The purpose of 
this project was to characterize the functional NES involved in nuclear export of HPV16 L2.  
DNA primers for mutant L2 proteins were designed to specifically target the two potential NES 
regions.  Two primers had mutations in the n-terminal located NES (nNES), while the other two 
primers had mutations in the c-terminal NES (cNES).  L2 nuclear retention mutants, RR297AA 
(“MS4”) and RTR313AAA (“MS5”), served as the templates for these NES mutations.  Previous 
analyses conducted by Shahan Mamoor demonstrated that L2 proteins containing the “MS4” or 
“MS5” mutations were localized pancellularly.  Using mutagenesis, the desired secondary 
mutations were introduced into the mutant L2 genes in order to create four, distinct mutants: 
RR297AA + P463_ (“MS4 T1”), RR297AA + V469_ (“MS4 T2), RTR313AAA + P463_ (“MS5 T1”), 
and RTR313AAA + V469_ (“MS5 T2”).   In order to visualize the localization of the mutant L2 
proteins, transfection assays in HeLa cells followed by fluorescence microscopy were performed.   
In contrast to the pancellular localization of the MS4 and MS5 L2 mutants, the “MS4 T1,” “MS4 
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T2,” “MS5 T1”, and “MS5 T2” mutants were all localized nuclearly.  These results suggest that 
deletion of the cNES inhibits nuclear export of the HPV16 L2 minor capsid protein.   
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Introduction___________________________________________________________________ 
Human Papillomaviruses 
 Human papillomaviruses (HPVs) are small, nonenveloped, icosahedral DNA viruses that 
specifically infect basal squamous epithelial cells.  Over 200 types of HPV have been 
characterized, about 40 of which are known to infect the mucosal cells of the anogenital and 
oropharyngeal tracts (Ili et al., 2011).  Depending on their oncogenic potential, these 40 HPVs 
are further classified into high-risk and low-risk types.  High-risk types, including HPV16, 18, 
31, and 45, have been implicated in the development of cervical and other anogenital cancers 
(zur Hausen, 2000). Low-risk types are associated with benign genital warts and include HPV6 
and 11.   
 HPV is considered to be the most common sexually transmitted disease in the United 
States.  Approximately 26% of females ages 14-59 are currently infected.  Women ages 20-24 
have the highest rate of infection at approximately 44% (Dunne et al., 2007).  For most 
individuals, the infection is cleared by the immune system within 18 months.  However, those 
individuals suffering from a persistent, high-risk HPV infection are at risk for developing cancer 
of the mucosal tissue.  More than 99% of cervical cancers and 20% of oropharyngeal cancers test 
positive for HPV DNA.  Significantly, cervical cancer is the second most common cancer and 
the fifth leading cause of death in women worldwide.  With over 500,000 new cases and 250,000 
deaths reported annually, cervical cancer remains an international public health concern 
(Longworth and Laimins, 2004).                    
 
Human Papillomavirus Genome and Life Cycle 
 The HPV genome consists of a single molecule of 8-kb double-stranded, circular DNA 
enclosed within an icosahedral capsid (Longworth and Laimins, 2004).  The genome can be 
divided into three distinct regions: an early (E) region, a late (L) region, and an upstream 
regulatory region (URR).  The early region contains 6 open reading frames (ORFs) that encode 6 
non-structural proteins (E1, E2, E4, E5, E6 and E7).  These genes are expressed early in the viral 
life cycle and facilitate viral transcription, DNA replication, and cell transformation.  E1 
functions as the viral helicase.  In complex with E1, E2 binds the viral origin of replication and 
recruits cellular polymerases (Longworth and Laimins, 2004).  E2 has also been implicated in the 
regulation of E6 and E7 expression.  E4 is responsible for arresting the cell in G2 phase 
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(Longworth and Laimins, 2004), while E5 appears to affect membrane signaling.  E6 and E7 act 
as oncogenes in high-risk HPVs.  By forming a complex with tumor suppressor protein p53 and 
the ubiquitin ligase E6AP, E6 promotes the ubiquitination and subsequent degradation of p53 
(Longworth and Laimins, 2004).  Without p53, the infected cell is unable to induce cell cycle 
arrest in response to DNA damage.  E7 has equally deleterious effects in that it binds the 
retinoblastoma protein (pRB) and prevents it from binding the E2F/DP1 transcription factors.  
This interference induces the transcription of the S-phase genes, thereby enabling viral 
replication (McLaughlin,-Drubin and Munger, 2009).   
 The late region contains 2 open reading frames (ORFs) that encode 2 structural proteins 
(L1 and L2).  In combination, the L1 and L2 proteins form the 55 nm icosahedral shell 
characteristic of HPVs.  360 L1 major capsid proteins assemble into 72 pentameric capsomeres.  
These capsomeres are held together via disulfide bonds between c-terminal arms of neighboring 
L1 proteins.  A single L2 protein is located at the center of each pentameric capsomere and 
provides structural stability.  Studies indicate that hydrophobic, intermolecular interactions exist 
between the c-terminal domain of one molecule of L2 at the center of a pentamere and the n-
terminal domain of a second molecule of L2 on a neighboring pentamere.  Although formation of 
L1-only capsomeres is possible, the existence of intermolecular interactions between L2 
molecules aids in capsid formation and provides additional structural stability (Pereira, 2009).    
 HPV infection begins with a microtrauma in the epithelium.  The virion binds a heparin-
sulfate receptor on the surface of a basal stem cell and is endocytosed through either a clathrin or 
caveolin mediated pathway.  Following disassembly in either a late endosome or lysosome, the 
viral genome is transported into the cell nucleus.  Initially, the virus is maintained as an 
extrachromosomal nuclear plasmid at 20-100 copies per cell.  During this time, the early stage 
proteins are expressed.  As the infected basal cell replicates, daughter cells migrate from the 
basal layer to the suprabasal layer and differentiate into epithelial cells.  It is at this time that the 
late stage proteins are expressed and the viral genome copy number increases to 500-1000 copies 
per cell (Longworth and Laimins, 2004; Fang et al., 2006).  To complete the cycle, new virions 
are assembled and shed into the surrounding environment at the epithelial surface (Jones and 
Münger, 1996).        
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Human Papillomavirus Vaccines 
 The currently available vaccines, Gardasil and Cervarix, are primarily recommended for 
prophylactic use.  Gardasil is a quadrivalent vaccine containing recombinant virus-like particles 
(VLPs) assembled from L1 proteins of HPV types 6, 11, 16, and 18.  HPV-6 and HPV-11 are 
associated with the majority of anogenital warts, while HPV-16 and HPV-18 are responsible for 
approximately 70% of the high-grade cervical lesions associated with cervical cancer (FUTURE 
II Study Group, 2007).  In a study conducted by Merck in 2007, 12,167 women were vaccinated 
with Gardasil and followed for a period of 3 years.  The primary composite endpoint included 
cervical intraepithelial neoplasia (Grade 2 or 3), adenocarcinoma in situ, or invasive carcinoma 
of the cervix (FUTURE II Study Group, 2007).  While the vaccine demonstrated 98% efficacy 
for the prevention of the primary composite endpoint, it achieved only 44% efficacy in the 
intention-to-treat population (FUTURE II Study Group, 2007).  In contrast to Gardasil, Cervarix 
is a bivalent vaccine containing recombinant VLPs assembled from L1 proteins of HPV types 16 
and 18.  Cervarix is 71% effective in the prevention of cervical intraepithelial neoplasias, grades 
2 or higher, in those individuals who have not been previously exposed to HPV. (Schauner and 
Lyon, 2010).   
 The major limitation of the L1 VLP vaccines, Gardasil and Cervarix, is that they are 
type-specific.  They are directed against the 70% of cervical cancers that are caused by HPV 
types 16 and 18.  In order to provide protection against more than 90% of cervical cancers, it 
would be necessary to generate a vaccine that incorporates VLPs from nine oncogenic HPV 
types (Jagu, et al., 2007).   
 Researchers at Johns Hopkins University are currently investigating the possibility of 
using the L2 minor capsid protein as an alternative to the L1 major capsid protein for HPV 
vaccine development.  Preclinical studies demonstrate that vaccination of rabbits with amino-
terminal L2 polypeptides induces protection against both homologous and heterologous 
papillomavirus types (Jagu, et al., 2007).   For example, Gambhira, et al. observed that 
vaccination of rabbits with HPV-16 L2 11-200 provides protection against both cutaneous and 
mucosal infection by cottontail rabbit papillomavirus (CRPV) and rabbit oral papillomavirus, 
even though CRPV and rabbit oral papillomavirus are evolutionarily divergent from of HPV-16 
(Gambhira, et al. and Jagu, et al., 2007).  However, the neutralizing titers and degree of 
protection conferred by monovalent L2 immunogens is greater for the homolgous-type virus than 
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for a heterologous-type virus (Jagu, et al.).  Essentially, vaccination with an HPV-16 L2-derived 
immunogen would induce a stronger, neutralizing response to an HPV type 16 infection than to 
an infection with another type of HPV. 
 In order to circumvent this problem, Jagu et al. designed a concatenated multitype L2 
fusion protein that contains cross-protective L2 epitopes from several human papillomavirus 
types (Jagu et al.).  Unlike the monovalent L2 immunogen, the concatenated multitype L2 fusion 
protein induced high neutralizing antibody titers against all heterologous HPVs tested when 
injected into mice.  Although an L2 multitype vaccine has yet to be tested in humans, these 
results suggest that the generation of a pan-oncogenic HPV vaccine is possible (Jagu et al.). 
 
HPV16 L2 Minor Capsid Protein 
 L2 is the minor capsid protein of human papillomavirus.  It is one of two structural 
proteins that is expressed late in the viral life cycle.  The role of L2 in HPV infection is 
multifaceted.  In addition to structural stability, it has been demonstrated that L2 facilitates viral 
entry into the cell and assists in nuclear localization of viral DNA. (Bordeaux et al., 2006) 
 HPV internalization into the host cell begins when L1 binds to a heparan sulfate 
proteoglycan (HSPG) receptor in the extracellular matrix.  The binding of L1 to HSPG is thought 
to trigger a conformational change that ultimately exposes the n-terminal region of the L2 
protein.  The first 9 amino acid residues of the n-terminal region are then cleaved by the 
proprotein convertase, furin.  Precleavage of the n-terminal domain of L2 enables HPV virions to 
infect cells lacking HSPG receptors (Richards et al., 2006).  This observation suggests that furin 
cleavage of L2, and not HSPG binding, is essential for viral entry.  Following L2 cleavage at the 
cell surface, the virion is internalized via either a clathrin-dependent or calveolin-dependent 
pathway.  The virion is the then transferred to an endosome, from which it is released via a 
membrane-destabilizing peptide located in the c-terminal region of the L2 protein (Kamper et al., 
2006).  Viral progression of the genome toward the nucleus is aided by the binding of the C-
terminal region of L2 with the microtubule motor protein, dynein.  Lastly, the presence of L2 
promotes the entrance of the HPV genome into the cell nucleus.  Nuclear localization signals on 
the L2 protein interact with several karyopherin β (Kap β) nuclear import receptors.  This 
interaction enables the transport of the HPV genome from the cytoplasm, through the nuclear 
pore complex, and into the cell nucleus where viral replication can begin (Pereira, 2009).   
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 Additionally, Pereira observed that, as the level of L2 expression increases, the viral 
components necessary for replication localize to nuclear domain 10 (ND10) (Pereira, 2009). 
These results suggest that the minor capsid protein of HPV is not only essential for capsid 
stabilization and viral entry, but also for genome replication within the host cell nucleus. 
 
Nuclear Import of HPV16 L2 Minor Capsid Protein  
 Karyopherins are soluble import receptors belonging to the karyopherin β / importin β 
(Kapβ/Impβ) superfamily.  Interaction between karyopherins and nucleoporins at the nuclear 
pore complex facilitates protein transport into the nucleus.  Following nuclear entry, the binding 
of Ran-GTP to Kapβ importins triggers protein release (Moroianu, 1999).         
 Two independent nuclear localization signals (NLSs) have been identified in the HPV16 
L2 protein.  One NLS is located in the n-terminal region (nNLS) (1MRHKRSAKRTKR13), while 
the second NLS is located in the c-terminal region (cNLS) (454LRKRRKRL462).   These NLSs 
play an essential role in nuclear import of the L2 minor capsid protein of HPV16 (Darshan et al., 
2004).  The nNLS of HPV16 L2 forms a complex with Kapβ2, Kapβ3, and Kapα2β1 heterodimers 
via the Kapα2 adapter.  The cNLS also interacts with Kapα2β1, however with lower affinity that 
the nNLS.  Significantly, the nNLS alone was unable to mediate nuclear import of a GST fusion 
protein via Kapβ2 and Kapβ3.  These results suggest that the nNLS requires other residues for 
nuclear import of HPV16 L2 (Darshan et al., 2004). 
 
Disruption of Nuclear Retention of HPV16 L2 Minor Capsid Protein 
 Research conducted in the Moroianu lab by graduate student Shahan Mamoor has 
demonstrated that nuclear retention of HPV16 L2 minor capsid protein can be disrupted by the 
introduction of mutations into the middle region of the L2 gene.  When analyzed independently, 
both the “MS4” mutation (RR297AA) and the “MS5” mutation (RTR313AAA) exhibited 
pancellular localization of L2.  Pancellular localization of HPV16 L2 implies that the protein is 
being both imported and exported from the cell nucleus.  Whereas previous analyses had 
demonstrated that nuclear import of the HPV16 L2 protein is karyopherin-dependent, the nuclear 
export mechanism of HPV16 L2 had not yet been determined.         
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Objectives and Hypothesis 
The characterization of the HPV16 L2 nuclear export signal became the focus of my 
research.  Using the “MS4” and “MS5” nuclear retention mutants as templates, my goal was to 
re-establish nuclear localization of the HPV16 L2 minor capsid protein by disrupting the nuclear 
export signal(s) (NESs).  Two regions that could potentially influence nuclear export were 
identified, one in the n-terminus (51MGVFFGGLGI60) and one in the c-terminus 
(462LPYFFDSVSL471).  Primers were designed to target these two, potential NESs.  Two primers 
contained mutations in the n-terminal NES (nNES) (S1 and S2).  The other two primers 
contained mutations in the c-terminal NES (cNES) (T1 and T2).  First, these four, secondary 
mutations were introduced into the L2 gene containing the “MS4” primary mutation.  Using 
fluorescence microscopy, the cellular localization of the resultant double mutants was analyzed.  
Nuclear localization of “MS4 T1” and “MS4 T2” suggested that the c-terminal region serves as a 
functional NES.  In order to confirm these results, the “T1” and “T2” secondary mutations in the 
c-terminal region were introduced into the L2 gene containing the “MS5” primary mutation.  
Nuclear localization of the HPV16 L2 double mutants “MS5 T1” and “MS5 T2” would indicate 
that the nuclear export signal of HPV16 L2 is located in the c-terminal region 
(462LPYFFDSVSL471).   
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Materials and Methods__________________________________________________________ 
Site-directed Mutagenesis 
 HPV16 L2 primary mutants, “MS4” and “MS5”, were generated using either 50 or 100 
ng of plasmid DNA in combination with 5 μl 10x reaction buffer, 125 ng each forward and 
reverse primer, 1 μl dNTP mix, and 1 μl PfuTurbo DNA polymerase.  Mutant DNA was 
synthesized in a PCR thermocycler according to the following parameters: 95°C for 30 seconds, 
95°C for 30 seconds (denaturation), 55°C for 60 seconds (annealing), 68°C for 6.5 minutes 
(extension), and 68°C for 10 minutes (final extension).  The denaturation, annealing, extension, 
and final extension segments were repeated for a total of 18 cycles.  Following temperature 
cycling, the reactions were placed on ice for 2 minutes and treated with 1 μl Dpn I restriction 
enzyme in order to digest the parental, methylated DNA.  After 1 hour of incubation at 37°C, 
mutant plasmids were transformed into XL1-Blue supercompetent cells.  Cultures were grown 
overnight at 37°C with shaking.  Mutant plasmids were then extracted using a Quantum 
Miniprep Kit and sent for sequencing (Eurofins MWG) in order to confirm the success of the 
mutagenesis. 
 Nuclear retention mutant “MS4” (pEGFP-HPV16 L2 RR297AA) served as the template 
for a series of secondary mutations.  The first set of secondary mutations targeted a potential, 
leucine-rich nuclear export signal in the n-terminal region (nNES) of the HPV16 L2 gene 
(51MGVFFGGLGI60).  Site-directed mutagenesis, as outlined above, was utilized in order to 
introduce the secondary mutations into the “MS4” template.  The two, resultant double-mutants 
were identified as “MS4 S1” (pEGFP-HPV16 L2 RR297AA + FF54AA) and “MS4 S2” (pEGFP-
HPV16 L2 RR297AA + LGI58AAA). 
 Nuclear retention mutant “MS4” served as the template for two, additional secondary 
mutations.  These secondary mutations targeted a potential, leucine-rich nuclear export signal in 
the c-terminal region (cNES) of the HPV16 L2 gene (462LPYFFDSVSL471).  First, the L2 protein 
was truncated at proline residue 463.  The resultant double-mutant was identified as “MS4 T1” 
(pEGFP-HPV16 L2 RR297AA + P463_).  Then, the L2 protein was truncated at valine residue 469.  
The resultant double-mutant was identified as “MS4 T2” (pEGFP-HPV16 L2 RR297AA + V469_).  
Site-directed mutagenesis, as outlined above, was utilized in order to introduce the secondary 
mutations into the “MS4” template.    
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 The effectiveness of the “T1” and “T2” NES mutations were also analyzed in the context 
of the “MS5” template (pEGFP-HPV16 L2 RTR313AAA).  Like “MS4”, the “MS5” primary 
mutation disrupted nuclear localization of the L2 minor capsid protein (Figure 8).  Again, the L2 
protein was truncated, first at proline residue 463 to create the resultant double-mutant “MS5 
T1” (pEGFP-HPV16 L2 RTR313AAA + P463_) and next at valine residue 469 to create the 
resultant double-mutant “MS5 T2” (pEGFP-HPV16 L2 RTR313AAA + V469_).  Site-directed 
mutagenesis, as outlined above, was utilized in order to introduce the secondary mutations into 
the “MS5” template.     
Graduate student, Shahan Mamoor, prepared the “MS4” and “MS5” primary mutants.  
Laboratory technician, Lauren Crosby, prepared the “MS4 S1” and “MS4 S2” double-mutants.  
Graduate student, Zeynep Onder, prepared the “MS4 T1”, “MS4 T2” and “MS5 T2” double-
mutants.  Undergraduate research assistant, Courtney Halista, prepared the “MS5 T1” double-
mutant.           
 
Cell Culture 
 The ATCC HeLa cell line was cultured in Dulbeccos Modified Eagle Medium (DMEM) 
supplemented with 10% heat-inactivated Fetal Bovine Serum and 1% Penicillin/Streptomyocin 
solution (Penstrep) at 37°C and 5% CO2.   
 
Transfection Assays 
 ATCC HeLa cells were plated on 12 mm poly-L-lysine-coated glass coverslips 24 hours 
prior to transfection and grown overnight to 50-70% confluency.  Transfection reactions for each 
well were prepared using 4 μl Fugene 6 Reagent (Roche Applied Science), 96 μl DMEM(-), and 
a concentration-dependent volume of the appropriate plasmid.  Following a 20 minute incubation 
period, cells were washed with 500 μl of DMEM(-).  100 μl of the plasmid preparation was then 
added to the appropriate well.  After 6 hours, the media was changed to 500 μl DMEM(+) (1% 
penicillin-streptomycin solution and 10% fetal bovine serum).  24 hours after the initial 
transfection, cells were washed three times with chilled PBS and fixed with 10% 
paraformaldehyde for 10 minutes.  Cells were then washed an additional three times with PBS.  
Coverslips were mounted on glass slides using Vectashield mounting medium (Vector Labs, CA) 
and DAPI (4,6,-diamidinophenylindole) in order to visual the cell nuclei.  Imaging and 
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quantitations of EGFP-fusion proteins were performed on a Zeiss Axioplan 2IE Microscope.  A 
minimum of four experiments were used for quantitative analysis.  The resultant quantitations 
are represented graphically with standard deviation (Figure 7 and Figure 11).         
  
Immunoblot Assays  
 ATCC HeLa cells were plated without coverslips 24 hours prior to transfection and 
grown overnight to 50-70% confluency.  Transfection reactions for each well were prepared and 
distributed as outlined above.  24 hours after the initial transfection, cells were placed on ice and 
the DMEM(+) media was removed.  20 μl 2X SDS-PAGE loading buffer with BME was added 
to each well to form a lysate.  Wells were scraped using the tip of a pipet for approximately 30 
seconds.  Lysates containing the same plasmid were combined in 0.7 μl tubes.  Tubes were 
vortexed and then boiled on a heat block at 99.5°C for approximately 10 minutes.  After 
microcentrifugation, 40 μl of each sample was subjected to SDS-PAGE and then transferred to 
nitrocellulose membrane.  Ponceau staining was used to visualize the proteins.  Lanes were then 
divided, split, and blocked overnight in 5% non-fat milk in PBS (pH 7.4) with 0.1% Tween-20 at 
4°C.  The following day, half of the lanes were incubated at room temperature for 1 hour with 1 
ml anti-L2 antibody solution containing RG-1 Mab Tissue Culture Sup in a 1:2000 dilution.  RG-
1 Mab Tissue Culture Sup was used to detect the presence of L2 protein.  The other half of the 
lanes were incubated at room temperature for 1 hour with 1 ml anti-GFP solution containing 
A.V. Monoclonal Antibody JL-8 in a 1:1000 dilution.  A.V. Monoclonal Antibody JL-8 was 
used to detect the presence of enhanced green fluorescent protein (EGFP).  Both sets of lanes 
were washed three times with 1X PBS and incubated at room temperature for 1 hour with the 
Goat anti-mouse HRP-conjugated secondary antibody in a 1:1000 dilution.  The signal was 
detected using an ECL Detection Kit (Amersham Biosciences) and exposure to x-ray film 
(Denville Scientific Inc.). 
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Results_______________________________________________________________________ 
Pancellular localization of HPV16 L2 “MS4” unaffected by secondary mutations in the n-
terminal region 
 Transfection assays of double-mutants “MS4 S1” (pEGFP-HPV16 L2 RR297AA + 
FF54AA) and “MS4 S2” (pEGFP-HPV16 L2 RR297AA + LGI58AAA) were conducted using 
primary mutant “MS4” (pEGFP-HPV16 L2 RR297AA) as the positive control and enhanced 
green fluorescent protein (EGFP) as the negative control.  As predicted, both the “MS4” primary 
mutant and EGFP control were localized pancellularly (Figure 4).  Both the “MS4 S1” and 
“MS4 S2 mutant proteins were also localized pancellularly (Figures not shown).  Neither the 
“S1” nor “S2” secondary mutations restored nuclear localization.  Experiments were performed 
by laboratory technician Lauren Crosby.   
 
Nuclear localization of HPV16 L2 “MS4” restored by secondary mutation in cNES 
 Transfection assays of double-mutants “MS4 T1” (pEGFP-HPV16 L2 RR297AA + P463_) 
and “MS4 T2” (pEGFP-HPV16 L2 RR297AA + V469_) were conducted using primary mutant 
“MS4” (pEGFP-HPV16 L2 RR297AA) as the positive control and enhanced green fluorescent 
protein (EGFP) as the negative control.  As predicted, both the “MS4” primary mutant and EGFP 
control were localized pancellularly (Figure 4).  Both the “MS4 T1” and “MS4 T2” mutant 
proteins were localized nuclearly (Figure 5 and Figure 6).   
 
Nuclear localization of HPV16 L2 “MS5” restored by secondary mutation in cNES 
      The effectiveness of the “T1” and “T2” NES mutations were analyzed in the context of 
the “MS5” template (pEGFP-HPV16 L2 RTR313AAA).  Transfection assays of double-mutants 
“MS5 T1” (pEGFP-HPV16 L2 RTR313AAA + P463_) and “MS5 T2” (pEGFP-HPV16 L2 
RTR313AAA + V469_) were conducted using primary mutant “MS5” as the positive control and 
enhanced green fluorescent protein (EGFP) as the negative control.  As predicted, both the 
“MS5” and EGFP controls were localized pancellularly (Figure 8).  Like the “MS4 T1” and 
“MS4 T2” double-mutants, the “MS5 T1” and “MS5 T2” double-mutants were localized 
nuclearly (Figure 9 and Figure 10).     
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Discussion____________________________________________________________________ 
 Experiments conducted by graduate student Shahan Mamoor in the Moroianu lab 
suggested that high risk HPV16 L2 minor capsid protein undergoes nuclear export.  The focus of 
my research was to characterize the associated nuclear export signal.  Previous data showed that 
nuclear localization of HPV16 L2 can be disrupted by introducing point mutations into the 
middle region of the HPV16 L2 sequence.  Using site-directed mutagenesis, the two arginine 
residues located at positions 297 and 298 were replaced by two alanine residues to create the 
“MS4” mutant (RR297AA).  Separately, the arginine-threonine-arginine residues located at 
positions 313-315 were replaced by three alanine residues to create the “MS5” mutant 
(RTR313AAA).   When analyzed independently, both HPV16 L2 “MS4” and “MS5” mutants 
were localized pancellularly in HeLa cells.   
 Interestingly, the RJA nuclear export inhibitor partially restored nuclear localization of 
the MS4 and MS5 nuclear retention mutants.  These data suggested that the HPV16 L2 protein 
undergoes nuclear export mediated by a leucine-rich nuclear export signal (NES).  Motif analysis 
revealed the presence of two potential NESs, one in the n-terminal region and one in the c-
terminal region. 
 The first series of experiments targeted the leucine-rich n-terminal region of the L2 
protein (51MGVFFGGLGI60).  Using the HPV16 L2 “MS4” construct as a template, two separate 
secondary mutations were introduced into the L2 sequence using site-directed mutagenesis.  In 
the first of two n-terminal secondary mutations, phenylalanine residues 54 and 55 were 
substituted with two alanine residues to create the resultant double-mutant RR297AA + FF54AA 
(“MS4 S1”).  In the second of two n-terminal secondary mutations, the leucine-glycine-
isoleucine residues at positions 58-60 were substituted with three alanine residues to create the 
resultant double-mutant RR297AA + LGI58AAA (“MS4 S2”).  Transfection assays in HeLa cells 
followed by fluorescence microscopy demonstrated that both the “MS4 S1” double-mutant and 
the “MS4 M2” double-mutant were localized pancellularly and that nuclear localization had not 
been restored.  These results suggested that the nuclear export signal was not located in the n-
terminus of the HPV16 L2 sequence. 
 Next, the leucine-rich c-terminal region of the HPV16 L2 protein (462LPYFFDSVSL471) 
was targeted.  Again, the HPV16 L2 “MS4” construct was used as a template for two separate 
secondary mutations.  In the first of two c-terminal secondary mutations, the protein was 
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truncated at proline residue 463 to create the resultant double-mutant RR297AA + P463_ (“MS4 
T1”).  In the second of two c-terminal secondary mutations, the protein was truncated at valine 
residue 469 to create the resultant double-mutant RR297AA + V469_ (“MS5 T2”).  Transfection 
assays in HeLa cells followed by fluorescence microscopy demonstrated that both the “MS4 T1” 
double-mutant and the “MS4 T2” double-mutant were localized nuclearly.  L2 was localized 
nuclearly in 79.5% of the cells transfected with EGFP-16 L2 MS4 T1 and in 83.7% of the cells 
transfected with EGFP-16 L2 MS4 T2 (Table 1).  These results suggested that the nuclear export 
signal of HPV16 L2 is located in the c-terminal region. 
 In order to confirm these results, the “T1” and “T2” truncations were introduced into the 
“MS5” construct.  The resulting double-mutants were identified as “MS5 T1” (RTR313AAA + 
P463_) and “MS5 T2” (RTR313AAA + V469_).  Transfection assays in HeLa cells followed by 
fluorescence microscopy demonstrated that both the “MS5 T1” double-mutant and the “MS5 T2” 
double-mutant were localized nuclearly.  L2 was localized nuclearly in 87.6% of the cells 
transfected with EGFP-16 L2 MS5 T1 and in 94.5% of the cells transfected with EGFP-16 L2 
MS5 T2 (Table 2).  Together with the results of the transfections utilizing the “MS4” c-terminal 
double-mutants, these observations suggest that the nuclear export signal of HPV16 L2 is located 
in the c-terminal region. 
 The identification and characterization of both the nuclear localization signals (NLSs) 
and nuclear export signal (NES) of HPV16 L2 is critical for understanding the mechanism of 
HPV infection.  Research conducted in the Moroianu lab concerning both the import and export 
pathways of HPV16 L2 could be helpful in the identification of specific drugs that could be used 
to inhibit nucleocytoplasmic trafficking of HPV16 L2 and, thus, prevent viral infection.     
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Figures_______________________________________________________________________ 
 
 
 
Figure 1: Schematic Representation of Human Papillomavirus Type 16 Genome 
           Image obtained from <http://www.microbiologybytes.com/virology/Papillomaviruses.    
           html>. 
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Figure 2: Schematic Representation of Human Papillomavirus Icosahedral Capsid 
         Image obtained from http://www.microbiologybytes.com/blog/tag/hpv/>. 
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Figure 3: Agarose Gel Electrophoresis of Human Papillomavirus Type 16 L2 Mutants 
    Agarose gel electrophoresis of HPV16 L2 mutants.  Plasmids were prepared  using the Quikchange Site-Directed 
     Mutagenesis Kit (Stratagene).  Lane 1 contains a 1 kb DNA ladder (New England Biolabs).  Lane 2 contains the                      
     HPV16 L2 “MS5” nuclear retention mutant as a positive control.  Lane 3 contains the HPV16 L2 “MS5 T1”     
     double- mutant.  Lane 4 contains the HPV16 L2 “MS5 T2” double-mutant.  Lane 5 contains the HPV16 L2    
     “MS5 L462A” double-mutant.  Lane 6 contains EGFP as a negative control. 
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Figure 4: Localization of HPV16 L2 “MS4” Nuclear Retention Mutant 
     HeLa cells were transfected with EGFP-HPV16 L2 “MS4” plasmids and examined 24 hours                 
       post-transfection using fluorescence microscopy.  EGFP fluorescence localizes the protein of  
                     interest.  DAPI staining localizes the cell nuclei.  Note the pancellular localization of the  
                     EGFP-HPV16 L2 “MS4” nuclear retention mutation.  Images courtesy of Zeynep Onder.                   
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Figure 5: Localization of HPV16 L2 “MS4 T1” Double Mutant 
                             HeLa cels were transfected with EGFP-HPV16 L2 “MS4 TI” plasmids and examined  
                             24 hours post-transfection using fluorescence microscopy.   DAPI staining localizes the 
                             cell nuclei.  EGFP fluorescence localizes the protein of interest.  Note the nuclear               
                             localization of the EGFP-HPV16 L2 “MS4 T1” double-mutant.  Images courtesy of Zeynep  
  Onder.                   
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Figure 6: Localization of HPV16 L2 “MS4 T2” Double Mutant 
                             HeLa cells were transfected with EGFP-HPV16 L2 “MS4 T2” plasmids and examined  
                             24 hours posttransfection using fluorescence microscopy.   DAPI staining localizes the 
                             cell nuclei.  EGFP fluorescence localizes the protein of interest.  Note the nuclear               
                             localization of the EGFP-HPV16 L2 “MS4 T2” double-mutant.  Images courtesy of  
  Zeynep Onder.                   
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HPV16 L2 Mutant Total # Nuclear Total # Pancellular Total # Cytoplasmic 
MS4 442 1410 5 
MS4 T1 1542 389 0 
MS4 T2 1205 238 0      
       
 
Table 1: Quantitations of the Localization of HPV16 L2 “MS4” Mutants 
 
 
 
 
HPV16 L2 Mutant % Nuclear % Pancellular % Cytoplasmic 
MS4 23.8 +/- 4.82 75.9 +/- 5.12 0.5 +/- 1.25 
MS4 T1 79.5 +/- 1.71 20.5 +/- 1.71 0 
MS4 T2 83.7 +/- 7.54 16.3 +/- 7.54 0 
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Figure 7: Graphical Representation of Quantitations of HPV16 L2 “MS4” Mutants 
       Nuclear localization of HPV16 L2 is restored when the “T1” and “T2” secondary mutations are added to  
       the “MS4” construct.  The black error bars indicate standard deviation.  Graph courtesy of Zeynep Onder.    
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Figure 8: Localization of HPV16 L2 “MS5” Nuclear Retention Mutant 
                    HeLa cells were transfected with EGFP-HPV16 L2 “MS5” plasmids and examined  24 hours   
                    post-transfection using fluorescence microscopy.   DAPI staining localizes the cell nuclei.  EGFP   
                    fluorescence localizes the protein of interest.  Note the pancellular localization of the EGFP- 
                    HPV16 L2 “MS5” nuclear retention mutant.                   
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Figure 9: Localization of HPV16 L2 “MS5 T1” Double Mutant 
                             HeLa cells were transfected with EGFP-HPV16 L2 “MS5 T1” plasmids and examined  
                             24 hours post-transfection using fluorescence microscopy.   DAPI staining localizes the 
                             cell nuclei.  EGFP fluorescence localizes the protein of interest.  Note the nuclear               
                             localization of the EGFP-HPV16 L2 “MS5 T1” double-mutant.                   
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Figure 10: Localization of HPV16 L2 “MS5 T2” Double Mutant 
                            HeLa cells were transfected with EGFP-HPV16 L2 “MS5 T2” plasmids and examined  
                            24 hours posttransfection using fluorescence microscopy.   DAPI staining localizes the 
                            cell nuclei.  EGFP fluorescence localizes the protein of interest.  Note the nuclear               
                            localization of the EGFP-HPV16 L2 “MS5 T2” double-mutant.                   
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Table 2: Quantitations of the Localization of HPV16 L2 “MS5” Mutants 
 
 
 
 
 
 
 
2.3.11 Nuclear Pancellular Cytoplasmic % Nuclear % Pancellular % Cytoplasmic 
HPV16 L2 MS5 2 26 0 7.1 92.9 0 
HPV16 L2 MS5 T1 71 8 0 89.9 10.1 0 
HPV16 L2 MS5 T2 79 5 0 94 6 0 
       
2.8.11 Nuclear Pancellular Cytoplasmic % Nuclear % Pancellular % Cytoplasmic 
HPV16 L2 MS5 0 0 0 0 0 0 
HPV16 L2 MS5 T1 18 2 0 90.0 10.0 0 
HPV16 L2 MS5 T2 8 0 0 100.0 0.0 0 
       
2.9.11 Nuclear Pancellular Cytoplasmic % Nuclear % Pancellular % Cytoplasmic 
HPV16 L2 MS5 0 28 0 0.0 100.0 0 
HPV16 L2 MS5 T1 130 46 0 73.9 26.1 0 
HPV16 L2 MS5 T2 9 1 0 90.0 10.0 0 
       
2.17.11 Nuclear Pancellular Cytoplasmic % Nuclear % Pancellular % Cytoplasmic 
HPV16 L2 MS5 0 97 0 0.0 100.0 0.0 
HPV16 L2 MS5 T1 193 7 0 96.5 3.5 0.0 
HPV16 L2 MS5 T2 51 3 0 94.4 5.6 0.0 
HPV16 L2 Mutant Total # Nuclear Total # Pancellular Total # Cytoplasmic 
MS5 2 153 0 
MS5 T1 412 63 0 
MS5 T2 147 9 0 
HPV16 L2 Mutant % Nuclear % Pancellular % Cytoplasmic 
MS5 1.3 +/- 3.55 98.7 +/- 48.93 0 
MS5 T1 86.7 +/- 9.63 13.3 +/- 9.63 0 
MS5 T2 94.2 +/- 4.11 5.8 +/- 4.11 0 
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Figure 11: Graphical Representation of Quantiations of HPV16 L2 “MS5” Mutants 
          Nuclear localization of HPV16 L2 is restored when the “T1” and “T2” secondary mutations are added to  
          the “MS5” construct.  The black error bars indicate standard deviation.   
 
.
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